Hepatitis B Vaccines

DNA Vaccine Elicits Protective Immune Response in Humans

Published in Hepatitis Weekly, December 21st, 1998

PowderJect Pharmaceuticals plc, Oxford, United Kingdom, and PowderJect Vaccines Inc., Madison, Wisconsin, announced results of a Phase Ib clinical trial of their hepatitis B prophylactic DNA vaccine.

The vaccine trial is the first human clinical trial to elicit a protective immune response with a DNA vaccine. Interim analysis showed that of the 11 subjects that have completed the vaccination schedule thus far, all seroconverted to antibody levels that are accepted as conferring protection against hepatitis B disease.

The trial enrolled 12 subjects and was designed to test the safety of the vaccine and measure the immune response elicited by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry